PARP Inhibitors: Improving Outcomes in Metastatic Prostate Cancer PARP Inhibitors: Improving Outcomes in Metastatic Prostate Cancer

Two new trials exploring this approach ― olaparib in the PROpel trial and niraparib in the MAGNITUDE trial –― had slightly different results.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news